Improving the safety of cell therapy products by suicide gene transfer - Wikidata - awgldk - TriplyDB

Improving the safety of cell therapy products by suicide gene transfer

Improving the safety of cell therapy products by suicide gene transfer

http://www.wikidata.org/entity/Q34453846

about

CAR models: next-generation CAR modifications for enhanced T-cell function New Strategies for the Treatment of Solid Tumors with CAR-T Cells Immune targeting of cancer stem cells in gastrointestinal oncology The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Novel immunotherapies in lymphoid malignancies Adoptive T-cell therapy for cancer: The era of engineered T cells CAR T Cell Therapy: A Game Changer in Cancer Treatment Advantages and applications of CAR-expressing natural killer cells Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Editorial: Improving the safety of cell therapy products by suicide gene transfer.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.New development in CAR-T cell therapy.New approaches for the immunotherapy of acute myeloid leukemia.Synthetic biology in cell-based cancer immunotherapy.NK cell-based cancer immunotherapy: from basic biology to clinical application.Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Modeling Natural Killer Cell Targeted Immunotherapies.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel Therapeutic Gene Editing Safety and Specificity.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase.T Cell Receptor Profiling in Type 1 Diabetes.Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.Human c-SRC kinase (CSK) overexpression makes T cells dummy.Distinct Responses of Stem Cells to Telomere Uncapping-A Potential Strategy to Improve the Safety of Cell Therapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.

P2860

Q26745600-CE5B0F9B-0851-44F1-BB2D-85A9EB16179C Q26748500-30DAE193-1035-4900-85B9-F79041668412 Q26749015-F9075630-4AD8-4666-8589-B014CFA5A3DD Q26774678-AD4FA922-6A0E-4474-AD96-1EE6246D068D Q26777394-6E6B50FB-17F1-4AE2-B412-FA7110898BAE Q26800611-653FDDD1-6BA8-42E5-8DD9-2CE37E939E5B Q26822769-E5CA87BE-796B-4B3C-87D8-994D811833EC Q28080875-F483CE2B-CDF5-4A7A-A33A-5576EE881A48 Q33833475-9C14111A-82D1-442A-857B-58A380CFC2B1 Q35711209-B0E0C3AC-E710-44EF-8F8B-B2CC054508CD Q35992678-9A0A662C-1B40-4D7D-AC1A-6060007B4ABB Q37559401-FBEE46CD-3B24-4958-8752-2A1C7E816AB3 Q37658246-0A65952D-D3C0-4D38-B4CC-AEDD63BD2A43 Q38482206-197122A0-0168-48F9-90C4-05B304DA628F Q38531361-6E81A3BC-59BC-42EF-A4FE-048A771E11C3 Q38640489-7E26E36A-3D91-407A-A98B-A75C74A0E28F Q38666862-4862CF80-B0CD-4A78-9680-B21CC37EA567 Q38773361-47742292-770D-4969-86B8-83B6FAD5EB35 Q38913549-A14A4F28-06FB-4717-83B8-DE816AB6B42E Q39161011-9B28838D-F0E9-4AF4-9850-FF3B723BF9A6 Q39208504-9C6149A4-E1DC-4C50-BC7C-734221096E25 Q39239278-9A9F3D5C-BEC3-41FC-9DD6-47519B7EE930 Q39249589-D80D3945-D78E-4A40-999F-A7C884D7AD9F Q40045823-A229113B-606B-45BD-9322-AE5E77C966FA Q40314122-8904C5B4-8F73-4E5F-B8B2-C85BE2FDC133 Q40418970-073F9841-92DA-4C97-9AD8-F7EDCC23A65D Q42374922-3BC54A7F-2A18-4FE0-92AE-9E1898E1609E Q46453590-5CC17F45-9EB2-4A9B-90EA-172310A6A87E Q48105379-A7101591-B327-4563-B5B7-0D1768D0F5DA Q48200984-950F74C1-4D07-4D79-83E1-5E2C70812246 Q55216327-9426ECAC-B5D7-4616-919E-1C7499D59528 Q55245977-A77CCA81-DED6-4FAD-9861-D097C96F543D

P2860

Improving the safety of cell therapy products by suicide gene transfer

http://www.wikidata.org/entity/Q34453846

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Improving the safety of cell therapy products by suicide gene transfer

@ast

Improving the safety of cell therapy products by suicide gene transfer

@en

Improving the safety of cell therapy products by suicide gene transfer

@nl

type

label

Improving the safety of cell therapy products by suicide gene transfer

@ast

Improving the safety of cell therapy products by suicide gene transfer

@en

Improving the safety of cell therapy products by suicide gene transfer

@nl

prefLabel

Improving the safety of cell therapy products by suicide gene transfer

@ast

Improving the safety of cell therapy products by suicide gene transfer

@en

Improving the safety of cell therapy products by suicide gene transfer

@nl

P1433

Q34453846-DF403956-1840-44AE-8298-315F3A3B6EF4

P1476

Q34453846-CC0FCDD6-CD38-4984-9E45-9A2CB0B32720

P2093

Q34453846-5A23577B-8DA3-4953-9DAC-D79D557731F3

Q34453846-79C9A876-A38B-443D-A175-9FE25F3FAB71

Q34453846-7AC734EF-A4C9-4CD4-BF13-EAF2FB56E116

Q34453846-8DC6E96B-173C-45AB-9601-0AB5CAEFD733

P2860

Q34453846-0318A728-B329-42F6-9E0E-85BCDE40BCF0

Q34453846-10EC5362-DDD4-4422-A9F2-BD8AC955F53F

Q34453846-19B0BCE1-001F-4356-8B68-D9E74C39F191

Q34453846-19F45932-F747-41D2-B0E0-437FF27A8F89

Q34453846-1A4A9E11-D1BC-465C-B306-B03807894D0C

Q34453846-1BB5B32E-F9CA-49B4-A92F-05A7E273D46C

Q34453846-1C03636F-6525-4587-BD4E-532226883D84

Q34453846-1C68EAA7-5C7B-4172-ABE2-B71C22341B63

Q34453846-1F226302-0C1F-4A84-8B06-AA8437D16A31

Q34453846-262B8F73-B972-4AC5-B5CB-A2CADE94206A

P304

Q34453846-263568CF-4228-46CE-836F-15B024A1D14D

P31

Q34453846-20BB1ED5-5602-4473-9EF8-31AB6AC05374

P356

Q34453846-903AAE00-7145-44C1-98B1-B155EE572BFF

P478

Q34453846-D09E5D91-EE59-4AFC-8692-6E1C851C38FA

P577

Q34453846-D7B0654E-7A52-4A3A-A274-99748AA356C9

P5875

Q34453846-04C4C9B9-D99D-4A49-A1F6-1E834C93CB7C

P698

Q34453846-424AFB15-2129-4A13-9845-B375588E499D

P921

Q34453846-50B6BAE7-8879-4CC7-9975-ECFAB21FE2FA

Q34453846-5AF6D5E8-5915-4BA0-9A56-784F6D9C6C62

P932

Q34453846-7F30D32F-9CF8-4E65-8AED-BC49F36C20BD

P356

FPHAR.2014.00254

P1433

Frontiers in Pharmacology

P1476

Improving the safety of cell therapy products by suicide gene transfer

@en

P2093

Antonio Di Stasi

http://www.w3.org/2001/XMLSchema#string

Benjamin S Jones

http://www.w3.org/2001/XMLSchema#string

Frederick Goldman

http://www.w3.org/2001/XMLSchema#string

Lawrence S Lamb

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

P304

254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2014.00254

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267639198

http://www.w3.org/2001/XMLSchema#string

P698

25505885

http://www.w3.org/2001/XMLSchema#string

P921

veteran suicide

P932

4245885

http://www.w3.org/2001/XMLSchema#string